Introduction {#S1}
============

Innate lymphoid cells (ILCs) are a heterogeneous population of immune cells with two defining characteristics: 1) they have lymphoid origin, differentiating from the common lymphoid progenitor (CLP) and dependent on IL-2Rγc signaling. 2) They lack antigen-specific receptors and therefore do not require the RAG proteins for development. Present throughout the body and enriched at mucosal surfaces in both human and mouse, ILCs promptly produce effector cytokines in response to stimulation with STAT-activating cytokines and alarmins of the IL-1 family \[[@R1], [@R2], and [@R3]\]. Based upon similarities in effector cytokine secretion and developmental requirements, ILCs can be divided into three populations: group 1 ILCs, group 2 ILCs, and group 3 ILCs ([Figure 1](#F1){ref-type="fig"}). IL-12, IL-21 IL-15 and IL-18 activate group 1 ILCs to produce interferon γ (IFN-γ); this group includes subsets such as T-bet^+^Eomes^+^ NK cells and T-bet^+^Eomes^−^ ILC1. IL-25, thymic stromal lymphopoietin (TSLP), and IL-33 trigger GATA-3^+^ ILC2 to produce type 2 cytokines such as IL-5 and IL-13. IL-23 and IL-1 prompt Rorγt^+^ ILC3 to produce IL-22 and/or IL-17. In adult, ILC3 subsets include lymphoid tissue-inducer like (LTi-like) cells and others that express the NK cell marker NKp46. As potent innate cytokine producers that respond to changes in the cytokine microenvironment, ILCs have demonstrated roles in early infection control, adaptive immune regulation, lymphoid tissue development, and in tissue homeostasis and repair \[[@R1], [@R2], and [@R3]\].

Group 1 ILCs {#S2}
============

Group 1 ILC are composed of cell populations functionally defined by their capacity to produce IFN-γ. In mouse, cells within this group uniformly express the surface receptors NKp46 and NK1.1, markers characteristic of NK cells \[[@R2]\]. However, NKp46^+^NK1.1^+^IFN-γ^+^ cells include a population, termed ILC1, which is developmentally and transcriptionally distinct from NK cells. ILC1, reported in the spleen, liver, intestine, and peritoneal cavity, can be discriminated from NK cells by the expression of the transcription factors (TF) T-bet and Eomes: NK cells are T-bet^+^Eomes^+^ while ILC1 are T-bet^+^Eomes^−^ \[[@R4], [@R5], [@R6], [@R7], [@R8], and [@R9]\]. It was previously thought that T-bet^+^Eomes^−^ cells were immature NK cells that acquire Eomes upon maturation \[[@R10]\]. However, it was recently shown that T-bet^+^Eomes^−^ cells do not give rise to T-bet^+^Eomes^+^ cells in steady state, suggesting that these cells are not immature but terminally differentiated \[[@R5]\]. In further support of this conclusion, an ILC progenitor in the bone marrow was capable of reconstituting T-bet^+^Eomes^−^ ILC1 cells but not T-bet^+^Eomes^+^ NK cells. Additionally, conditional *Eomes*^−/−^ mice maintained ILC1 populations and lacked mature NK cells, while *Tbx21*^−/−^ mice lack ILC1 but maintained mature NK cells in the BM and gut \[[@R4] and [@R10]\].\]. Also, the transcription factor PLZF is important for liver ILC1 but not liver NK cell development \[[@R11]\]. Finally, the transcription factor GATA-3 has been shown to be critical for ILC1 development \[[@R12], [@R13], and [@R14]\], yet whether it is also important for NK cell development \[[@R15]\] remains to be clarified.

In addition to developmental differences, some ILC1 have been shown to be tissue resident, contrasting with NK cells, which recirculate in the blood \[[@R7] and [@R9]\]. Surface markers can distinguish ILC1 and NK cells, although they may be variable depending upon the tissue examined. ILC1 have been found to be CD122^+^CD49a^+^CD49b^−^ TRAIL^+^CD127^+^CD69^+^CXCR3^+^CXCR6^+^ while NK cells are CD122^+^CD49a^−^CD49b^+^TRAIL^−^ CD127^−^CD69^−^CXCR3^−^CXCR6^−^ ([Table 1](#T1){ref-type="table"}) \[[@R4], [@R5], [@R6], [@R7], [@R8], and [@R9]\]. Importantly, although ILC1 express the IL-7Rα (CD127) they do not require IL-7 for their development and are present in *Il7*^−/−^ mice. Instead, like NK cells, ILC1 critically require IL-15 signaling and are absent in *Il15*^−/−^ mice \[[@R4] and [@R5]\].

Although IFN-γ is the defining cytokine of both NK cells and ILC1, ILC1 are more proficient in the production of TNF-α, and in the liver preferentially produce IL-2 \[[@R5] and [@R7]\]. NK cells are well known for their capacity to kill target cells through the release of granules containing granzymes and perforin, but whether ILC1 also have cytotoxic capabilities is currently unclear. Compared to liver NK cells, liver ILC1 show differential expression of granzymes and reduced expression of perforin, yet are equally capable of cytolytic degranulation and inducing target cell death in vitro \[[@R5], [@R7], and IMN Robinette *et al.*, unpublished\]. Given the phenotypic and functionally similarity between NK cells and ILC1, it will be important to see if these two cell subsets play complementary or distinct roles during antiviral and antitumor immunity.

Additionally, there are still other cell types that do not exactly fit into the NK cell/ILC1 dichotomy among various tissues. For example, the small intestine contains an intraepithelial ILC1 population which is developmentally T-bet dependent but only partially IL-15 dependent \[[@R16]\]. The small intestine lamina propria (siLP) also contains a plastic subset of former Rorγt^+^ ILC3 that converts to IFN-γ-producing cells with surface markers difficult to distinguish from ILC1 ('ex-Rorγt ILC3') \[[@R2]\]. The salivary gland maintains a large population of cells which are both T-bet^+^Eomes^+^ yet poor producers of IFN-γ \[[@R17]\]. In the uterus, there are also NK cells that are still present in both T-bet and Eomes deficient mice \[[@R7]\]. Finally, human tissues contain an ILC1 population that lacks any NK cell marker \[[@R18]\]. More work is needed to delineate the developmental relations of these cell populations to each other and most importantly the functional role they may play during the immune response within the tissue where they reside. Based on current evidence, group 1 ILCs are a spectrum of overlapping cell subsets that produce IFN-γ rather than bimodal, well defined cell lineages.

Group 2 ILCs {#S3}
============

ILC2 are the most homogenous ILC class, expressing largely conserved markers in all tissues, such as IL-7Ra, IL2Ra (CD25), Sca-1, KLRG1, and the IL-33 receptor ST2 ([Table 1](#T1){ref-type="table"}) \[[@R2]\]. An additional innate IL-25 responsive and type 2 cytokine producing population, called MPP^Type2^, has also been reported. However, unlike ILC2, this IL-7Rα and ST2 negative population retains the ability to differentiate into myeloid cells \[[@R19] and [@R20]\] and is thus not strictly an ILC population. ILC2 are dependent on the TFs GATA-3, Rorα, TCF-1 and Notch for their development, which has recently been reviewed \[[@R2] and [@R21]\]. Functionally, ILC2 are well known to produce IL-5, IL-13, and Amphiregulin in a GATA-3 dependent manner \[[@R12]\] as well as GATA-3 independent IL-4 \[[@R12] and [@R22]\]. Recent research has focused on the how ILC2 contribute to the normal immune response through crosstalk with stromal and other immune cells, both in the innate and adaptive responses.

The first emerging mechanism that position ILC2 in the normal immune response is through positive feedback loops with other innate immune cells. Early in the immune response, various cellular sources including stroma, macrophages, NKT cells \[[@R23]\], and mast cells \[[@R24]\] produce IL-33, a danger signal produced during necrosis and downstream of danger associated molecular patterns (DAMPs) \[[@R25]\] that has recently been reviewed \[[@R26]\]. IL-33 directly activates ILC2 and mast cells through its receptor ST2, enhancing their recruitment \[[@R27]\]. Activated mast cells further enhance ILC2 activity through the secretion of the non-caspase proteases chymase and tryptase, which increase IL-33 potency \[[@R27]\], and production of the strong ILC2 activator PDG~2~ \[[@R26]\]. This positive feedback cycle is fortified by ILC2 proliferative signals from basophils via IL-4 production \[[@R29] and [@R30]\]. In turn, ILC2 produced IL-5 feedback on eosinophils to promote innate effector responses, by regulating their recruitment and activity \[[@R31] and [@R32]\]. Interestingly, the helminth *H. polygyrus* has developed mechanisms to circumvent this pathway, as its secretory products prevent IL-33 release and subsequent ILC2 activation and eosinophil recruitment \[[@R33]\]. Thus, crosstalk between other innate immune cells and ILC2 promote an early feed forward type 2 response.

A second theme investigated recently has been the role of ILC2 in the priming and development of an appropriate T~H~2 response. Mechanisms of ILC2-T~H~2 crosstalk are both indirect and direct. ILC2 indirectly promote T~H~2 differentiation through early type 2 cytokine production. For example, in a papain model of allergic lung inflammation, ILC2-produced IL-13 induces DC migration to the mediastinal lymph node, which was a key event responsible for T~H~2 priming \[[@R34]\]. Similarly, ILC2 harvested from an atopic dermatitis model and adoptively transferred intradermally into wildtype mice led to enhanced T~H~2 responses in the draining lymph node \[[@R29]\]. ILC2 also directly lead to T~H~2 responses via expression of MHC II, which facilitates antigen presentation to T cells at a similar capacity to B cell \[[@R35] and [@R36]\]. Functionally, this interaction is relevant, as mice depleted of ILC2 or lacking ILC2 expression of MHC II had impaired ability to mount appropriate T cell responses during *N. brasiliensis* infection \[[@R36]\]. ILC2 can also directly activate CD4+ T cells via IL-4 production and OX40L costimulation \[[@R37]\]. Thus, ILC2 priming of the adaptive immune responses is an important component of their physiologic function and a mechanism of deregulation during pathology.

Group 3 ILCs {#S4}
============

This group of ILCs is highly complex and includes many reported subsets in adult mice, as well as additional fetal and neonatal LTi subsets that have been long recognized as a key factor for lymphoid organogenesis. ILC3 are grouped together based on shared expression of the transcription factor Rorγt, but vary in their expression of T-bet, cell surface markers, and cytokine production profiles. In the adult, these subsets include 4 populations found at greatest frequency in the siLP ([Table 1](#T1){ref-type="table"}): CD4^+^ and a CD4^−^ subsets of CCR6^+^ Nkp46^−^ Rorγt^+^ LTi-like cells \[[@R38]\]; NKp46^−^ Rorγt^+^ T-bet^+^ ILC3 progenitors \[[@R38]\]; NKp46^+^ Rorγt^+^ T-bet^+^ Notch-dependent ILC3 \[[@R39], [@R40], [@R41], and [@R42]\]. One additional subset of IL-17 and IFN-γ producing Rorγt^+^ Nkp46^−^ ILC3 is present in the large intestine \[[@R43]\]. Similar to group 1 ILCs, group 3 ILCs are particularly complicated due to evidence of diverging progenitors for different subsets that share many of the same functions and cell surface markers. A current, simplified model of differentiation posits that there is progressive differentiation from NKp46^−^ ILC3, to NKp46^+^ ILC3, and finally to NKp46^+^ NK1.1^+^ ex-Rorγt ILC3 \[[@R2]\]. In contrast, CCR6^+^ NKp46^−^ LTi-like do not give rise to NKp46^+^ ILC3 after transfer \[[@R40]\]. Recent gene expression profiling in our lab demonstrate that CD4^+^ and CD4^−^ NKp46^−^ LTi-like subsets have minimal transcriptional differences and are unlikely to be functionally distinct (IMN Robinette *et al.*, unpublished). It remains possible that the diversity of these subsets depends on the microenvironment or their origin from either fetal or adult progenitors.

As all Rorγt^+^ ILC3 can produce IL-22, many recent studies have described new ways that this cytokine mediates barrier integrity during homeostatic conditions and mucosal remodeling during injury and infection. IL-22 is a member of the IL-10 family of cytokines, which acts through an IL-22 dimeric receptor only expressed by non-immune stromal cells. IL-22 is produced by ILC3 in response to IL-23 stimulation by CX3CR1^+^ inflammatory monocytes and CD11b^+^ DC \[[@R44] and [@R45]\]. This ILC3-DC priming has recently been shown to be dependent on CXCR6-CXCL16 \[[@R45]\] and defects in CXCR6 lead to loss of protection from *Citrobacter rodentium*, an attaching and effacing pathogen well known to be controlled by IL-22. Within the GI tract, ILC3 locally regulate commensals and pathogens by inducing intestinal epithelial fucosylation via IL-22 in response to microbial signals \[[@R46] and [@R47]\]. Systemic IL-22 protects the gastrointestinal epithelium from potentially pathogenic symbionts, or pathobionts, after prior injury by inducing complement factor C3 production from the liver \[[@R48]\]. Additionally, IL-22 in concert with IL-18 are critical to the prevention and resolution of intestinal norovirus infection, demonstrating novel antiviral functions of this cytokine \[[@R49]\]. Although IL-22 signaling appears to be mostly beneficial to the host, it can become pathogenic in certain circumstances, such as the anti-CD40 model of colitis in RAG deficient animals, mediated in part by IL-22-induced secretion of neutrophil chemoattractants by epithelial cells and dysregulated recruitment of neutrophils \[[@R50]\]. Another potential pathological effect of ILC3-mediated IL-22 production is tumorigenesis, which occurs downstream of sustained STAT3 activation in epithelial cells in mice. Indeed, cells with ILC3 consistent phenotypes (CD3^−^ IL22^+^) can be found in human adenocarcinomas \[[@R51]\]. Notably, this defect may be due in part to IL-17, as loss of IL-17 in RAG deficient mice diminishes adenoma development \[[@R52]\]. Thus, ILC3 produced IL-22 has both host protective and pathological roles within the gastrointestinal tract.

Beyond IL-22, ILC3 also respond to the microbiome and host micronutrient status to modulate the immune response. In response to commensal flora driven IL-1β, ILC3 produce GM-CSF, which expands colonic DCs and macrophages that support T-reg development. Thus, ILC3 may also contribute to oral tolerance \[[@R53]\]. Furthermore, recent functional analyses of ILC3 have demonstrated that their expression of MHC II facilitates antigen presentation, which combined with the absence of costimulatory molecules, enables ILC3 to induce T cell tolerance \[[@R54]\]. Interestingly, recent evidence demonstrates that the immune response can also be modified through micronutrients availability. In this vein, vitamin A deficiency leads to a blunted ILC3 but enhanced ILC2 response \[[@R55]\], while vitamin D deficiency enhances the ILC3 response \[[@R56]\]. As the availability of some micronutrients is directly regulated by the microbiome, this may represent a conserved pathway important for immunoregulation.

ILC Development from a Common Progenitor {#S5}
========================================

Within the bone marrow, the common lymphoid progenitor (CLP) gives rise to all ILC lineages, as well as B and T cells \[[@R2]\]. The earliest progenitor with restricted lineage potential all ILCs has recently been identified as the CXCR6^+^ αLP (α~4~β~7~ expressing CLP; also known as the common innate lymphoid progenitor-CILP) ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) \[[@R57]\]. The αLP shows multi-lineage differentiation, including NK, ILC1, ILC2, and all ILC3 both *in vitro* and upon transplantation *in vivo*. This progenitor is dependent on the basic leucine zipper TF NFIL3, consistent with other reports describing a lack of all ILCs in *Nfil3*^−/−^ mice \[[@R58] and [@R59]\]. Of note, the NFIL3 requirement for Group 1 ILC development can be bypassed following some infections \[[@R60]\] and/or environmental factors \[[@R7] and [@R17]\]. Moreover, Group 1 ILC subsets in the salivary gland, uterus, and possibly liver appear to develop independently of NFIL3. Therefore the αLP may not be completely dependent on NFIL3 or some ILC may develop from a non-αLP progenitor.

After the αLP, lineage divergence of ILC populations has recently been demonstrated by two reports \[[@R4] and [@R11]\]. One study used reporter mice for the TF Id2 (a transcriptional repressor of E2-family TFs) to identify a Id2^+^Lin^−^IL-7Ra^+^α~4~β~7~^+^CD25^−^PLZF^+/−^ Common Helper-Like Innate Lymphoid Progenitor (CHILP). Upon transfer, the CHILP gave rise to Eomes^−^ ILC1, ILC2, NKp46^+^ ILC3 and NKp46^−^ ILC3 including the CD4^+^ LTi-like subset, but not Eomes^+^ NK cells. Although the CHILP was identified by Id2 expression, the importance of this TF may not be limited to this progenitor as *Id2*^−/−^ mice lack NK cells and some ILC1, ILC2, and ILC3 \[[@R61] and [@R62]\]. Moreover, Id2 identifies an early NK cell restricted progenitor, the pre-pro NK \[[@R63]\].

In another study, lineage tracing with combined PLZF^GFPCre^ × Rosa26-YFP reporter mice revealed that most ILCs were GFP^−^ (thus not expressing PLZF) \[[@R11]\]. However, these cells were YFP^+^ (expressed PLZF at some point) and found to derive from a PLZF^high^Lin^−^IL-7Ra^+^cKit^+^ α~4~β~7~^high^ CXCR6^−^ progenitor, called the innate lymphoid cell progenitor (ILCP). Transfer of these ILCPs with competitor CLPs demonstrated that ILCP cells gave rise to greater frequencies of ILCs, corresponding to a progenitor skewed toward ILC development. ILCPs efficiently generated ILC1, ILC2, and some ILC3, but were poor at generating NK cells or LTi-like subsets. One caveat is that this study identified ILC1s by the lack of expression of CD49b and not Eomes expression, a more definitive maker. Given the more restricted differentiation of the ILCP, the current model of ILC development would place it downstream of the CHILP. PLZF deficiency causes some defects in ILC1 and ILC2 development, suggesting that it is not essential for all ILC development. Interestingly, GATA-3 is first expressed in the ILCP and some models of GATA-3 deficiency lead to selective reduction of ILC1, ILC2, and some ILC3, but not NK cells or LTi-like cells, in agreement with the progenitor capacity of the ILCP \[[@R11], [@R12], [@R13],[@R14], and [@R15]\].

Concluding remarks {#S6}
==================

With the increasing complexity of ILC subsets, it becomes important to clearly define the developmental origin and the functional impact of each of these subsets. While there may be redundancy among subsets, it is clear that each ILC group and some subsets within each group have specialized functions. Many studies have shown the beneficial roles of ILC in host defense against pathogens. Current studies are shifting the focus on the interaction of ILC with the commensal flora, the relevance of this interaction in tolerance and, when interaction is deregulated, in the immune-mediated disease pathogenesis, including IBD, psoriasis, atopic dermatitis, and asthma. While ILCs were originally studied in gut, lung and lymphoid organs, more studies are investigating their roles in other organs and tissues, such as skin, liver and exocrine glands. It will be interesting to see how the developmental stages of tissues analyzed promotes the plasticity and activation of a given ILC population. Better understanding of ILC cell biology will likely reveal new mechanisms of immunity and immunopathology and avenues of intervention in many human diseases.
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###### Highlights

-   Group 1 ILC comprise diverse subsets producing IFN-γ

-   Group 2 ILC crosstalk with T~H~2 for immune responses

-   Group 3 ILC modulate immune response to the microbiome and micronutrient status

-   Bone marrow progenitors give rise to multiple ILC lineages

![ILC developmental tree with known restricted progenitors and the differentiated cell populations they give rise to. ILCs are divided into group 1, group 2, and group 3 based upon common effector cytokine production.](nihms-661765-f0001){#F1}

###### 

Surface markers and transcription factor expression used to differentiate ILC precursors ILC populations.

                     Phenotypic Markers                                                                          Transcription Factors                                                                     
  ------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------------------
  **Progenitors**    CLP                                                                                         Lin^−^, cKit^low^, CD127^+^, Sca1^low^, Flt3^+^, α~4~β~7~^−^                              
  aLP/CILP           Lin^−^, cKit^low^, CD127^+^, Sca1^low^, Flt3^−^,α~4~β~7~^+^, CXCR6^+^                       Id2^−^, PLZF^−^, GATA-3^−^                                                                
  CHILP              Lin^−^, CD127^+^, Flt3^−^, α~4~β~7~^+^, CD25^−^                                             Id2^+/−^, PLZF^+/−^, GATA-3^−^                                                            
  ILCP               Lin^−^, cKit^+^, CD127^+^, α~4~β~7~^high^, CXCR6^−^                                         Id2^+^, PLZF^high^, GATA-3^+/−^                                                           
  **Group 1 ILCs**   NK cells                                                                                    NK1.1^+^, NKp46^+^, CD49a^−^, CD49b^+^, TRAIL^−^, CD127^−^, CD69^−^, CXCR6^−^, CXCR3^−^   T-bet^+^, Eomes^+^
  ILC1               NK1.1^+^, NKp46^+^, CD49a^+^, CD49b^−^, TRAIL^+^, CD127^+/−^, CD69^+^, CXCR6^+^, CXCR3^+^   T-bet^+^, Eomes^−^                                                                        
  **Group 2 ILCs**   ILC2                                                                                        Lin^−^, CD127^+^, CD25^+^, Sca1^+^, KLRG1^+^, ST2^+^                                      GATA-3^+^
  **Group 3 ILCs**   NKp46+ ILC3                                                                                 NK1.1^−^, NKp46^−^, CD127^+^                                                              Rorgt^+^, T-bet^+^
  NKp46− ILC3        NK1.1^−^, NKp46^+^, CD127^+^                                                                Rorgt^+^, T-bet^+^                                                                        
  LTi Like           NK1.1^−^, NKp46^−^, CD127^+^, CD4^+/−^, CCR6^+^                                             Rorgt+, T-bet^−^                                                                          
